434 related articles for article (PubMed ID: 31511064)
1. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
[TBL] [Abstract][Full Text] [Related]
2. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Cheong JE; Sun L
Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
[TBL] [Abstract][Full Text] [Related]
3. 1-Methyl-D-tryptophan activates aryl hydrocarbon receptor, a pathway associated with bladder cancer progression.
Matheus LHG; Dalmazzo SV; Brito RBO; Pereira LA; de Almeida RJ; Camacho CP; Dellê H
BMC Cancer; 2020 Sep; 20(1):869. PubMed ID: 32907554
[TBL] [Abstract][Full Text] [Related]
4. Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells.
Liu Y; Liang X; Yin X; Lv J; Tang K; Ma J; Ji T; Zhang H; Dong W; Jin X; Chen D; Li Y; Zhang S; Xie HQ; Zhao B; Zhao T; Lu J; Hu ZW; Cao X; Qin FX; Huang B
Nat Commun; 2017 May; 8():15207. PubMed ID: 28488695
[TBL] [Abstract][Full Text] [Related]
5. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
Klar R; Michel S; Schell M; Hinterwimmer L; Zippelius A; Jaschinski F
Cancer Immunol Immunother; 2020 Jan; 69(1):57-67. PubMed ID: 31802183
[TBL] [Abstract][Full Text] [Related]
6. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.
Campesato LF; Budhu S; Tchaicha J; Weng CH; Gigoux M; Cohen IJ; Redmond D; Mangarin L; Pourpe S; Liu C; Zappasodi R; Zamarin D; Cavanaugh J; Castro AC; Manfredi MG; McGovern K; Merghoub T; Wolchok JD
Nat Commun; 2020 Aug; 11(1):4011. PubMed ID: 32782249
[TBL] [Abstract][Full Text] [Related]
7. Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy.
Kober C; Roewe J; Schmees N; Roese L; Roehn U; Bader B; Stoeckigt D; Prinz F; Gorjánácz M; Roider HG; Olesch C; Leder G; Irlbacher H; Lesche R; Lefranc J; Oezcan-Wahlbrink M; Batra AS; Elmadany N; Carretero R; Sahm K; Oezen I; Cichon F; Baumann D; Sadik A; Opitz CA; Weinmann H; Hartung IV; Kreft B; Offringa R; Platten M; Gutcher I
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37963637
[TBL] [Abstract][Full Text] [Related]
8. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy.
Zhai W; Zhou X; Zhai M; Li W; Ran Y; Sun Y; Du J; Zhao W; Xing L; Qi Y; Gao Y
Sci China Life Sci; 2021 Apr; 64(4):548-562. PubMed ID: 32737851
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model.
Meng X; Du G; Ye L; Sun S; Liu Q; Wang H; Wang W; Wu Z; Tian J
Int J Immunopathol Pharmacol; 2017 Sep; 30(3):215-226. PubMed ID: 28604143
[TBL] [Abstract][Full Text] [Related]
10.
Fong W; Li Q; Ji F; Liang W; Lau HCH; Kang X; Liu W; To KK; Zuo Z; Li X; Zhang X; Sung JJ; Yu J
Gut; 2023 Nov; 72(12):2272-2285. PubMed ID: 37770127
[TBL] [Abstract][Full Text] [Related]
11. IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells
Amobi-McCloud A; Muthuswamy R; Battaglia S; Yu H; Liu T; Wang J; Putluri V; Singh PK; Qian F; Huang RY; Putluri N; Tsuji T; Lugade AA; Liu S; Odunsi K
Front Immunol; 2021; 12():678999. PubMed ID: 34025677
[TBL] [Abstract][Full Text] [Related]
12. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
13. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8
Dey S; Sutanto-Ward E; Kopp KL; DuHadaway J; Mondal A; Ghaban D; Lecoq I; Zocca MB; Merlo LMF; Mandik-Nayak L; Andersen MH; Pedersen AW; Muller AJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690770
[TBL] [Abstract][Full Text] [Related]
14. Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens.
Engin AB; Engin A
Adv Exp Med Biol; 2021; 1275():339-356. PubMed ID: 33539022
[TBL] [Abstract][Full Text] [Related]
15. Ganoderic acid Me induces the apoptosis of competent T cells and increases the proportion of Treg cells through enhancing the expression and activation of indoleamine 2,3-dioxygenase in mouse lewis lung cancer cells.
Que Z; Zou F; Zhang A; Zheng Y; Bi L; Zhong J; Tian J; Liu J
Int Immunopharmacol; 2014 Nov; 23(1):192-204. PubMed ID: 25138378
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.
Wang S; Campos J; Gallotta M; Gong M; Crain C; Naik E; Coffman RL; Guiducci C
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):E7240-E7249. PubMed ID: 27799536
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of vascular adhesion protein-1 enhances the anti-tumor effects of immune checkpoint inhibitors.
Kinoshita T; Sayem MA; Yaguchi T; Kharma B; Morii K; Kato D; Ohta S; Mashima Y; Asamura H; Kawakami Y
Cancer Sci; 2021 Apr; 112(4):1390-1401. PubMed ID: 33453147
[TBL] [Abstract][Full Text] [Related]
18. Intelligent nanovesicle for remodeling tumor microenvironment and circulating tumor chemoimmunotherapy amplification.
Huai M; Wang Y; Li J; Pan J; Sun F; Zhang F; Zhang Y; Xu L
J Nanobiotechnology; 2024 May; 22(1):257. PubMed ID: 38755645
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation of human CD8+ T cells induced by TCR triggering or homeostatic cytokines.
Weber WP; Feder-Mengus C; Chiarugi A; Rosenthal R; Reschner A; Schumacher R; Zajac P; Misteli H; Frey DM; Oertli D; Heberer M; Spagnoli GC
Eur J Immunol; 2006 Feb; 36(2):296-304. PubMed ID: 16385630
[TBL] [Abstract][Full Text] [Related]
20. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
